tirzepatide news september 27 2025 🧬 New data from the SUMMIT trial reveals that long-term (Zepbound) may significantly improve kidney function in patients with obesity, chronic kidney disease (CKD), and heart failure with preserved ejection fraction ( Lilly's next-gen obesity drug shows

Both semaglutide and tirzepatide underwent randomized, placebo-controlled trials for obesity, with marked reduction of weight as shown below

True allergy A true allergy occurs when your immune system identifies a drug as a harmful substance and launches an immune response, resulting in an allergic reaction

Effects of semaglutide treatment on the psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial In this medfyle In a small randomised study presented at EADV 2025, semaglutide showed significant reduction of PASI and inflammatory markers in people with psoriasis, obesity, and T2D

Adolescents 12 years of age and older with an initial BMI at or above the 95th percentile for age and sex

Individual results vary consult with a BHRC provider for personalized medical advice